Feedback
Meperidine and Metabolite, Serum or Plasma, Quantitative
2002756
Ordering Recommendation
Monitor patient adherence.
Mnemonic
MEPER SP
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Tue, Thu
Reported
1-6 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA).  
Specimen Preparation
Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 1 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate). Specimens exposed to repeated freeze/thaw cycles.  
Remarks
Submit With Order
1.  Dose - List drug amount of drug and include the units of measure
2.  Route - List the route of administration (IV, oral, etc.)
3.  Dose Frequency -  Indicate  how often the dose is administered (per day, per week or as needed, etc.)
4.  Type of Draw - Indicate the type of blood draw (Peak, Trough, Random, etc.)  
Stability
After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years  
Reference Interval
Effective August 17, 2015
 
Drugs Covered Cutoff Concentrations
Meperidine 2 ng/mL
Normeperidine (meperidine metabolite) 5 ng/mL
Interpretive Data
Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Positive cutoff
:
Meperidine: 2 ng/mL
Normeperidine: 5 ng/mL

For medical purposes only; not valid for forensic use.

The presence of metabolite(s) without parent drug may indicate use of parent drug during the prior week.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

See Compliance Statement B: www.aruplab.com/CS
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
 
CPT Code(s)
80362; (Alt code G6056)
Components
Component Test Code*Component Chart NameLOINC
2002757Normeperidine, S/P, Quant10996-7
2002758Meperidine, S/P, Quant3745-7
2011511Meperidine Dose 
2011512Meperidine Dose Frequency 
2011513Meperidine Route 
2011514Meperidine Type of Draw 
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Centralgin
  • Demerol
  • Dispadol
  • Dolantin
  • Dolosal
  • Dolsin
  • Isonipecaine
  • Lidol
  • Mepergan
  • Meperidine (Meperidine & Metabolite-Confirmation/Quantitation-Serum or Plasma)
  • meperidine blood concentration
  • meperidine blood level
  • Normeperidine
  • Pethanol
  • Pethidine